Cargando…
Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo
Novel therapeutic targets are needed to better treat osteosarcoma, which is the most common bone malignancy. We previously developed mouse osteosarcoma cells, designated AX (accelerated bone formation) cells from bone marrow stromal cells. AX cells harbor both wild-type and mutant forms of p53 (R270...
Autores principales: | Shimizu, Takatsune, Sugihara, Eiji, Takeshima, Hideyuki, Nobusue, Hiroyuki, Yamaguchi, Rui, Yamaguchi-Iwai, Sayaka, Fukuchi, Yumi, Ushijima, Toshikazu, Muto, Akihiro, Saya, Hideyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688353/ https://www.ncbi.nlm.nih.gov/pubmed/36429043 http://dx.doi.org/10.3390/cells11223614 |
Ejemplares similares
-
Calcitriol exerts an anti‐tumor effect in osteosarcoma by inducing the endoplasmic reticulum stress response
por: Shimizu, Takatsune, et al.
Publicado: (2017) -
Up-Regulation of Imp3 Confers In Vivo Tumorigenicity on Murine Osteosarcoma Cells
por: Ueki, Arisa, et al.
Publicado: (2012) -
Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells
por: Yamaguchi, Sayaka I, et al.
Publicado: (2015) -
Regulatory roles of fibronectin and integrin α5 in reorganization of the actin cytoskeleton and completion of adipogenesis
por: Uetaki, Megumi, et al.
Publicado: (2022) -
Accumulation of genetic and epigenetic alterations in normal cells and cancer risk
por: Takeshima, Hideyuki, et al.
Publicado: (2019)